Your browser doesn't support javascript.
loading
In vitro toxicity of the galanin receptor 3 antagonist SNAP 37889.
Koller, Andreas; Rid, Raphaela; Beyreis, Marlena; Bianchini, Rodolfo; Holub, Barbara S; Lang, Andreas; Sternberg, Felix; Brodowicz, Bernhard; Velickovic, Ognjen; Jakab, Martin; Kerschbaum, Hubert; Önder, Kamil; Kofler, Barbara.
Afiliación
  • Koller A; Laura Bassi Centre of Expertise THERAPEP, Research Program for Receptor Biochemistry and Tumor Metabolism, Department of Pediatrics, Paracelsus Medical University, Müllner Hauptstraße 48, 5020 Salzburg, Austria.
  • Rid R; Division of Molecular Dermatology, Department of Dermatology, Paracelsus Medical University, Müllner Hauptstraße 48, 5020 Salzburg, Austria.
  • Beyreis M; Department of Cell Biology, University of Salzburg, Hellbrunnerstraße 34, 5020 Salzburg, Austria; Institute of Physiology and Pathophysiology, Paracelsus Medical University, Strubergasse 21, 5020 Salzburg, Austria; Gastein Research Institute, Paracelsus Medical University, Strubergasse 21, 5020 Salz
  • Bianchini R; Laura Bassi Centre of Expertise THERAPEP, Research Program for Receptor Biochemistry and Tumor Metabolism, Department of Pediatrics, Paracelsus Medical University, Müllner Hauptstraße 48, 5020 Salzburg, Austria.
  • Holub BS; Laura Bassi Centre of Expertise THERAPEP, Research Program for Receptor Biochemistry and Tumor Metabolism, Department of Pediatrics, Paracelsus Medical University, Müllner Hauptstraße 48, 5020 Salzburg, Austria.
  • Lang A; Laura Bassi Centre of Expertise THERAPEP, Research Program for Receptor Biochemistry and Tumor Metabolism, Department of Pediatrics, Paracelsus Medical University, Müllner Hauptstraße 48, 5020 Salzburg, Austria.
  • Sternberg F; Laura Bassi Centre of Expertise THERAPEP, Research Program for Receptor Biochemistry and Tumor Metabolism, Department of Pediatrics, Paracelsus Medical University, Müllner Hauptstraße 48, 5020 Salzburg, Austria.
  • Brodowicz B; Laura Bassi Centre of Expertise THERAPEP, Research Program for Receptor Biochemistry and Tumor Metabolism, Department of Pediatrics, Paracelsus Medical University, Müllner Hauptstraße 48, 5020 Salzburg, Austria.
  • Velickovic O; Division of Molecular Dermatology, Department of Dermatology, Paracelsus Medical University, Müllner Hauptstraße 48, 5020 Salzburg, Austria.
  • Jakab M; Institute of Physiology and Pathophysiology, Paracelsus Medical University, Strubergasse 21, 5020 Salzburg, Austria.
  • Kerschbaum H; Department of Cell Biology, University of Salzburg, Hellbrunnerstraße 34, 5020 Salzburg, Austria.
  • Önder K; Division of Molecular Dermatology, Department of Dermatology, Paracelsus Medical University, Müllner Hauptstraße 48, 5020 Salzburg, Austria; Procomcure Biotech GmbH, Austria.
  • Kofler B; Laura Bassi Centre of Expertise THERAPEP, Research Program for Receptor Biochemistry and Tumor Metabolism, Department of Pediatrics, Paracelsus Medical University, Müllner Hauptstraße 48, 5020 Salzburg, Austria. Electronic address: B.Kofler@salk.at.
Neuropeptides ; 56: 83-8, 2016 04.
Article en En | MEDLINE | ID: mdl-26725588
Galanin and its receptors (GAL1, GAL2, GAL3) modulate a range of neuronal, immune and vascular activities. In vivo administration of SNAP 37889 (1-phenyl-3-[[3-(trifluoromethyl)phenyl]imino]-1H-indol-2-one), a potent small non-peptidergic antagonist of GAL3, was reported to reduce anxiety- and depression-related behavior, ethanol consumption, and antagonizes the effect of galanin on plasma extravasation in rodent models. Accordingly, SNAP 37889 has been proposed as a potential therapeutic agent to treat anxiety and depression disorders. Therefore, we evaluated the toxicity of SNAP 37889 to different cell types. Our experiments revealed that SNAP 37889 (≥10µM) induced apoptosis in epithelial (HMCB) and microglial (BV-2) cell lines expressing endogenous GAL3, in peripheral blood mononuclear cells and promyelocytic leukemia cells (HL-60) expressing GAL2, and in a neuronal cell line (SH-SY5Y) lacking galanin receptor expression altogether. In conclusion, SNAP 37889 is toxic to a variety of cell types independent of GAL3 expression. We caution that the clinical use of SNAP 37889 at doses that might be used to treat anxiety- or depression- related diseases could have unexpected non-galanin receptor-mediated toxicity, especially on immune cells.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Apoptosis / Receptor de Galanina Tipo 3 / Indoles Límite: Animals / Humans Idioma: En Revista: Neuropeptides Año: 2016 Tipo del documento: Article País de afiliación: Austria

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Apoptosis / Receptor de Galanina Tipo 3 / Indoles Límite: Animals / Humans Idioma: En Revista: Neuropeptides Año: 2016 Tipo del documento: Article País de afiliación: Austria